Biocartis Group Stock

Biocartis Group FCF Margin

Delisted·Jan 21, 2026

The Free Cash Flow Margin of Biocartis Group (BCART.BR) as of Aug 10, 2026 is -81.40 %. In the previous year, Free Cash Flow Margin was -143.92 % — a change of -43.44% (higher).

FCF Margin

-81.40 %

YoY

-43.44%

Last updated:

Free Cash Flow Margin of Biocartis Group is 2026 -81.40 % . Free Cash Flow Margin of Biocartis Group was 2025 -143.92 % . It decreases by -43.44% higher compared to the previous year.
Access this data via the Eulerpool API

Biocartis Group Stock analysis

What does Biocartis Group do? Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocartis Group stock

Free Cash Flow Margin of Biocartis Group is -81.40 % in 2026.

Free Cash Flow Margin of Biocartis Group changed from -143.92 % to -81.40 %, representing a -43.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Biocartis Group since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Biocartis Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Biocartis Group

All Key Metrics — Biocartis Group